Hoppa till innehållet

OMXSPI+1,18%

S&P 500+0,16%

FTSE 100+0,05%

DAX+0,35%

NIKKEI+0,73%
Active Biotech Interim Report Q1 2024

FIRST QUARTER IN BRIEF

  • Preparations ongoing for start of the clinical proof of concept studies with tasquinimod in myelofibrosis
  • The expansion cohort of the study in multiple myeloma is ongoing according to plan

EVENTS AFTER THE END OF THE PERIOD

  • Start of enrollment to the clinical phase I biodistribution study with laquinimod eye drops (April 3)


FINANCIAL SUMMARY

SEK MJan-MarFull year

202420232023
Net sales---
Operating profit/loss-10.7-11.8-46.5
Profit/loss after tax-10.5-11.5-45.8
Earnings per share (SEK)-0.03-0.04-0.17
Cash and cash equivalents (at close of period)25.430.236.2


The report is also available at www.activebiotech.com.

This information was provided to the media, through the agency of the contact persons set out below, for publication on May 8, 2024 at 18.00 CET.

For further information, please contact:

Helén Tuvesson, CEO, +46 46 19 21 56, helen.tuvesson@activebiotech.com
Hans Kolam, CFO, +46 46 19 20 44, hans.kolam@activebiotech.com

About Active Biotech

Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that develops first-in-class immunomodulatory treatments for oncology and immunology indications with a high unmet medical need and significant commercial potential. Active Biotech currently holds three projects in its portfolio, of which tasquinimod and laquinimod are wholly owned small molecule immunomodulators with a mode of action that includes modulation of myeloid immune cell function. The projects are in clinical development for hematological malignancies and inflammatory eye disorders, respectively. The company's core focus is on the development of tasquinimod in myelofibrosis, a rare blood cancer, where clinical proof-of-concept studies are being prepared. Also ongoing is a clinical Phase Ib/IIa study in multiple myeloma. Laquinimod is in clinical development for the treatment of non-infectious uveitis. A clinical phase I program with a topical ophthalmic formulation is ongoing to support phase II development together with a partner. The third pipeline project is naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, which is in a phase Ib/II clinical program in patients with advanced solid tumors. Please visit www.activebiotech.com for more information.

Attachments

AB Rapport 2024 Q1 En

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera